USNA - Earnings announcements

Company Continues to Make Significant Progress on Transformation to Becoming a Leading Omnichannel Health and Wellness Platform USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended April 4, 2026. Key Financial Results First Quarter 2026 vs. First Quarter 2025 Net sales of $250 million versus $250 million. Net earnings of $7.5 million versus $9.4 million. Diluted EPS of $0.41 as compared with $0.49. Adjusted diluted EPS(1) of $0.61 as compared with $0.73. Adjusted EBITDA(2) of $28.4 million versus $29.8 million. Core Nutritional Active Customers of 404,000 versus 459,000. Hiya Active Monthly Subscribers of 186

USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2026 results will be released after the close of market on Tuesday, May 5, 2026. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, May 6, 2026 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures high-

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026. Key Financial and Operating Results   Q4 2025   Q4 2024   FY 2025   FY 2024 Net sales $226.2   $213.6   $925.3   $854.5 Net (loss) earnings* $-1.8   $4.5   $10.8   $42.0 Diluted EPS $-0.10   $0.23   $0.58   $2.19 Adjusted diluted EPS(1) $0.60   $0.64   $1.93   $2.59 Adjusted EBITDA(2) $27.3

USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA's strategy, including the Company's initial fiscal year 2026 sales outlook. Preliminary Fiscal Year 2025 Net Sales Results The Company currently anticipates fiscal year 2025 consolidated net sales of approximately $925 million, ahead of its most recently issued guidance of approximately $920 million. Initial Fiscal Year 2026 Net Sales Outlook The Company is issuing its initial net sales outlook for fi

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025. Key Financial Results Third Quarter 2025 vs. Third Quarter 2024 Net sales of $214 million versus $200 million, representing 7% year-over-year growth. Net loss of -$6.5 million versus net earnings of $10.6 million. Diluted EPS of -$0.36 as compared with $0.56. Adjusted diluted EPS(1) of -$0.15 as compared with $0.56. Adjusted EBITDA(2) of $13.8 million versus $24.6 million. Direct selling Active Customers of 388,000 versus 452,000. Hiya Active Monthly Subscribers of 193,400. Q3 2025 Financial Performance Consolidated Results

USANA Health Sciences, Inc. (NYSE:USNA) ("the Company," "USANA") today announced that it has updated the timing of the release of its third quarter 2025 financial results, which had previously been scheduled for Tuesday, October 21, 2025. The Company will now report third quarter 2025 financial results after the close of market on Wednesday, October 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the follow

USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary results for the third quarter ended September 27, 2025. The Company anticipates third quarter 2025 net sales will be approximately $214 million, which compares with $200 million in the prior-year period. Earnings from operations are expected to be $1.2 million for the current-year quarter, or 0.6% of net sales, as compared to $15.6 million in the third quarter of 2024. "Third quarter operating results came in below expectations, primarily due to softer-than-expected sales and Brand Partner productivity during the rollout of our enhanced Brand Partner compensation plan," said Jim Brown, President and Chief Executive Office

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal second quarter ended June 28, 2025. Key Financial Results Second Quarter 2025 vs. Second Quarter 2024 Net sales of $236 million versus $213 million, representing 11% year-over-year growth. Net earnings of $9.7 million versus $10.4 million. Diluted EPS of $0.52 as compared with $0.54. Adjusted diluted EPS(1) of $0.74 as compared with $0.54. Adjusted EBITDA(2) of $30 million versus $27 million. Direct selling Active Customers of 418,000 versus 468,000. Hiya Active Monthly Subscribers of 200,400. Company reiterates fiscal year 2025 outlook. Q2 2025 Financial Performance C

USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter 2025 results will be released after the close of market on Tuesday, July 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, July 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 million versus $228 million, representing year-over-year growth of 10% and 12% in constant currency. Net earnings of $9.4 million versus $16.5 million. Diluted EPS of $0.49 as compared with $0.86. Adjusted diluted EPS(1) of $0.73 as compared with $0.86. Adjusted EBITDA(2) of $30 million versus $33 million. Direct selling Active Customers of 459,000 versus 494,000. Hiya Active Monthly Subscribers of 224,000. Company reiterates fiscal year 2025 outlook. Q1 2025 Financia

USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2025 results will be released after the close of market on Tuesday, April 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, April 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures hi

USANA Health Sciences, Inc. (NYSE:USNA) (the "Company") today announced financial results for its fiscal fourth quarter and fiscal year ended December 28, 2024. The Company completed the acquisition of a 78.8% controlling ownership stake of Hiya Health Products, LLC ("Hiya") on December 23, 2024. Consequently, the Company's fourth quarter and fiscal year 2024 include the effect of less than a week of Hiya's operating results, which were not significant to the Company's consolidated results for the same periods. In light of the Hiya acquisition, the Company is now including metrics for Adjusted diluted EPS(1) and Adjusted EBITDA(2). Net earnings, Diluted EPS, Adjusted diluted EPS(1) and Adju

USANA Health Sciences, Inc. (NYSE:USNA) today announced that fourth quarter and fiscal year 2024 results will be released after the close of market on Tuesday, February 25, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, February 26, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA de

Hiya is a fast-growing, emerging leader of high-quality children's health & wellness products. Broadens USANA's reach into the highly attractive direct-to-consumer channel driven by Hiya's powerful subscription model with runway for sustainable future growth. Expected to be immediately accretive to 2025 adjusted EBITDA. 9/30/2024 LTM net sales of $103 million, LTM net income of $19 million, and LTM adjusted EBITDA of $22 million. The Company will discuss the transaction during a conference call on Monday, December 23, 2024, at 5:00 PM ET. USANA Health Sciences, Inc. (NYSE:USNA) (the "Company," "USANA"), today announced its acquisition of a 78.8% controlling ownership stake in Hiya

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 28, 2024. Key Financial & Operating Results Third quarter net sales were $200 million versus $213 million during Q3 2023. Third quarter diluted EPS was $0.56 as compared with $0.59 during Q3 2023. Company updates fiscal year 2024 net sales and diluted EPS outlook to approximately $850 million and $2.45, respectively (previously $850 million to $880 million and $2.40 to $2.55). Q3 2024 Financial Performance Consolidated Results Net Sales $200 million -6% vs. Q3 2023     No meaningful YOY FX impact     -6% sequentially D

USANA Health Sciences, Inc. (NYSE:USNA) today announced that third quarter 2024 results will be released after the close of market on Tuesday, October 22, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, October 23, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufacture

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal second quarter ended June 29, 2024. Key Financial & Operating Results Second quarter net sales were $213 million versus $238 million during Q2 2023. Second quarter diluted EPS was $0.54 as compared with $0.89 during Q2 2023. Company updates fiscal year 2024 net sales and diluted EPS outlook to $850 million to $880 million and $2.40 to $2.55 (previously $850 million to $920 million and $2.40 to $3.00). Q2 2024 Financial Performance Consolidated Results Net Sales $213 million -11% vs. Q2 2023     -8% constant currency vs. Q2 2023  

USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter 2024 results will be released after the close of market on Tuesday, July 23, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, July 24, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 30, 2024. Key Financial & Operating Results First quarter net sales were $228 million versus $248 million during Q1 2023, and increased 2% sequentially in constant currency. First quarter diluted EPS was $0.86 as compared with $0.95 during Q1 2023. Company reiterates fiscal year 2024 net sales and diluted EPS outlook of $850 million to $920 million and $2.40 to $3.00. Q1 2024 Financial Performance Consolidated Results Net Sales $228 million -8% vs. Q1 2023     -5% constant currency vs. Q1 2023    

USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2024 results will be released after the close of market on Tuesday, April 30, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, May 1, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures hi

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended December 30, 2023. Key Financial Results & Guidance Fourth quarter net sales were $221 million versus $228 million during Q4 2022 and $213 million during Q3 2023. Fourth quarter diluted EPS was $0.87 as compared with $0.66 during Q4 2022. Fiscal year 2023 net sales were $921 million as compared with $999 million during fiscal year 2022. Fiscal year 2023 diluted EPS totaled $3.30 versus $3.59 during fiscal year 2022. Company provides initial fiscal year 2024 net sales and diluted EPS guidance of $850 million to $920 million and $2.40 to $3.00, respect

USANA Health Sciences, Inc. (NYSE:USNA) today announced that fourth quarter and fiscal year 2023 results will be released after the close of market on Tuesday, February 6, 2024. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, February 7, 2024 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA deve

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 30, 2023. Key Financial & Operating Results Third quarter net sales were $213 million versus $233 million during Q3 2022. Third quarter diluted EPS was $0.59 as compared with $0.78 during Q3 2022. Company narrows fiscal year 2023 net sales and diluted EPS outlook to $900 million to $920 million and $2.80 to $3.05, respectively (previously $900 million to $950 million and $2.65 to $3.30). Q3 2023 Financial Performance Consolidated Results Net Sales $213 million -9% vs. Q3 2022 -7% constant currency vs. Q3 2022 -$5 million YOY F

USANA Health Sciences, Inc. (NYSE:USNA) today announced that third quarter results will be released after the close of market on Tuesday, October 24, 2023. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, October 25, 2023 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal second quarter ended July 1, 2023. Key Financial & Operating Results Second quarter net sales were $238 million versus $264 million during the second quarter of 2022. Second quarter diluted EPS was $0.89 as compared with $1.00 during the second quarter of 2022. Fiscal 2023 net sales and diluted EPS guidance updated to $900 to $950 million and $2.65 to $3.30, respectively, from $875 million to $950 million and $2.40 to $3.30. Q2 2023 Financial Performance Consolidated Results Net Sales $238 million -10% vs. Q2 2022 -6% constant currency vs. Q2 2022 -$10 millio

USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter results will be released after the close of market on Tuesday, July 25, 2023. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, July 26, 2023 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures high-

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended April 1, 2023. Key Financial & Operating Results First quarter net sales were $248 million versus $228 million for the fourth quarter of 2022 and $273 million during the first quarter of 2022. First quarter diluted EPS was $0.95 as compared with $0.66 for the fourth quarter of 2022 and $1.15 during the first quarter of 2022. Generated $13 million of operating cash flow during the quarter. Fiscal 2023 net sales and diluted EPS guidance updated to $875 to $950 million and $2.40 to $3.30, respectively, from $850 million to $950 million and $2.35 to $3.30. Q1 2023 Financ

USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter results will be released after the close of market on Tuesday, April 25, 2023. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, April 26, 2023 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures high

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and full year ended December 31, 2022. Key Financial & Operating Results Fourth quarter net sales were $228 million versus $267 million during the prior-year period. Fourth quarter diluted EPS was $0.66 as compared with $1.03 during Q4 2021. Fiscal year 2022 net sales were $999 million as compared with $1,186 million during fiscal year 2021. Fiscal year 2022 diluted EPS totaled $3.59 versus $5.73 during fiscal year 2021. Fiscal year 2022 operating cash flow totaled $104 million. Company reiterates fiscal year 2023 net sales and diluted EPS outlook of $850 million to $950 mill

USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary fiscal year 2022 results and initial guidance for fiscal year 2023 ahead of its presentation at the 25th Annual ICR Conference. The Company currently anticipates fiscal year 2022 net sales of approximately $995 million and diluted earnings per share of approximately $3.65. The Company's most recently issued fiscal year 2022 guidance anticipated net sales between $955 and $975 million and diluted earnings per share between $3.15 and $3.40. Total Active Customers were approximately 490,000 at year-end. Net sales for the fourth quarter and full-year benefitted from incremental sales in mainland China during the last two weeks

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended October 1, 2022. Key Financial & Operating Results Third quarter net sales were $233 million as compared with $274 million during the third quarter of the prior year. Third quarter diluted EPS totaled $0.78 versus $1.36 during the third quarter of 2021. Company revises fiscal 2022 net sales and diluted EPS outlook to $955 million to $975 million and $3.15 to $3.40, respectively. Q3 2022 Financial Performance Consolidated Results Net Sales $233 million -15% vs. prior-year quarter -9% constant currency vs. prior-year quarter -$15 million YOY FX impact, or -6

USANA Health Sciences, Inc. (NYSE:USNA) today announced that third quarter results will be released after the close of market on Tuesday, October 25, 2022. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's website (http://ir.usana.com) under the Investor Relations section of the site. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, October 26, 2022 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures hig

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal second quarter ended July 2, 2022. Key Financial & Operating Results Second quarter net sales were $264 million as compared with $337 million during the second quarter of the prior year. Second quarter diluted EPS totaled $1.00 versus $1.87 during the second quarter of 2021. Company reiterates fiscal 2022 net sales and diluted EPS outlook of $1.015 billion to $1.065 billion and $3.85 to $4.45, respectively. Q2 2022 Financial Performance Consolidated Results Net Sales $264 million -21% vs. prior-year quarter -18% constant currency vs. prior-year quarter -$10.9 million YOY FX i

USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary results for the second quarter ended July 2, 2022, and provided an updated outlook for fiscal year 2022. The Company anticipates that second quarter 2022 net sales will be approximately $265 million, which compares with $337 million in the prior-year period. Earnings per share for the quarter are expected to be approximately $1.05, which compares with $1.87 during the second quarter of 2021. "Our sales performance during the second quarter was below expectations, as COVID-related lockdowns, restrictions, and other disruptions continued in mainland China and other markets," said Kevin Guest, Chief Executive Officer and Chai

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended April 2, 2022. Key Financial & Operating Highlights First quarter net sales were $273 million as compared with $308 million during the first quarter of the prior year. First quarter diluted EPS totaled $1.15 versus $1.45 during the first quarter of 2021. Company revises fiscal 2022 net sales and diluted EPS outlook to $1.1 billion to $1.2 billion and $5.00 to $5.70, respectively. Q1 2022 Financial Performance Consolidated Results Net Sales $272.9 million -11% vs. prior-year quarter -10% constant currency vs. prior-year quarter +2% constant currency sequent

USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter results will be released after the close of market on Tuesday, April 26, 2022. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's website (http://ir.usana.com) under the Investor Relations section of the site. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, April 27, 2022 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures high-qu

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its full year and fiscal fourth quarter ended January 1, 2022. Key Financial & Operating Highlights Fiscal year 2021 net sales grew 5% to $1.186 billion. Reported fiscal year 2021 diluted EPS totaled $5.73. Fourth quarter net sales reached $267 million and diluted EPS were $1.03. Company provides initial 2022 net sales guidance of $1.125 to $1.225 billion and initial diluted EPS guidance of $5.25 to $6.00. The Company maintains a 52/53-week fiscal year. Fiscal 2020 was a 53-week year and included one additional week of sales in the fourth quarter. FY 2021 Financial Performance Consolidated Results

USANA Health Sciences, Inc. (NYSE:USNA) today announced that fourth quarter and FY 2021 results will be released after the close of market on Tuesday, February 8, 2022. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's website (http://ir.usana.com) under the Investor Relations section of the site. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, February 9, 2022 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and man

USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended October 2, 2021, which were modestly ahead of the preliminary outlook the Company provided on September 16, 2021. Key Financial & Operating Highlights Third quarter net sales were $274.4 million as compared with $298.5 million during the third quarter of the prior year. Third quarter diluted EPS were $1.36 versus $1.44 during the third quarter of 2020. Reiterates fiscal 2021 net sales and diluted EPS outlook, which was provided on September 16, 2021. Company expects to generate approximately $130 million of free cash flow in fiscal 2021. Q3 2021 Financial Performance Co

USANA Health Sciences, Inc. (NYSE:USNA) today announced that third quarter 2021 results will be released after the close of market on Tuesday, October 26, 2021. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's website (http://ir.usana.com) under the Investor Relations section of the site. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, October 27, 2021 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufacture

USANA Health Sciences, Inc. (NYSE:USNA) today announced record financial results for its fiscal second quarter ended July 3, 2021. Key Financial & Operating Highlights Second quarter net sales increased 30.1% year-over-year to a record $336.8 million. Second quarter diluted EPS increased 41.7% year-over-year to $1.87. Active Customers increased 8.8% year-over-year to a record 652,000. Reiterates 2021 net sales and diluted EPS outlook. Q2 2021 Financial Performance Consolidated Results Net Sales $336.8 million +30.1% vs. prior-year quarter +20.3% constant currency vs. prior-year quarter +$25.2 million YOY FX impact, or +9.8% Diluted EPS $1.87 +41.7%